Jing Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Sun has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Xuan Zhou
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 shared publications- Bin Chen
Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication Dong Du
Nanfang Hospital Southern Medical University Guangzhou China
1 shared publication- Guiyong Jiang
Department of Orthopaedics, Division of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
1 shared publication - Guo Chen
Department of Spine Surgery, Department of Orthopaedics, The Seventh Affiliated Hospital, Southern Medical University, Foshan China
1 shared publication - Haihao Liu
Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- 1 November 2025
- Published by Springer Nature in International Orthopaedics
- Vol. 50 (1) , 47-56
Treatment of fracture in haemophilia: a retrospective study
Purpose Fractures in persons with haemophilia (PWH) exhibit similarities and distinctions compared to typical fractures. However, complications confer an added increase in the risk of fractures. This study aimed to summarize the treatment experience of fractures in PWH based on a classification. Methods A retrospective cohort study was conducted on PWH between 2001 and 2023. The classification was developed into three types according to PWH’s clinical presentations and imaging findings. Subsequently, the distribution and distinctions among subtypes were analyzed, followed by an exploration of risk factors for fracture-related complications. Results A total of 61 fractures in PWH met the inclusion and exclusion criteria. The median follow-up duration was 6.87 years. Type II and III fractures in PWH exhibited a longer time of fracture healing and hospital stay, along with increased fracture-related complication rates. In further analysis, the operative time and intraoperative blood loss also increased significantly. Furthermore, compared to non-surgical approaches, the surgical treatment appeared to reduce the incidence of fracture-related complications. Next, the femur was identified as the most frequently fractured site. Plate fixation was the predominant surgical approach for types II (20/29) and III (8/13). Conclusion This study reviews treatment experience for fractures in PWH according to a classification and stresses the importance of surgery. The classification may provide a potential strategy for post-operative care. However, further classification is required.
- 1 November 2025
- Published by Springer Nature in International Orthopaedics
- Vol. 50 (1) , 47-56
Treatment of fracture in haemophilia: a retrospective study
Purpose Fractures in persons with haemophilia (PWH) exhibit similarities and distinctions compared to typical fractures. However, complications confer an added increase in the risk of fractures. This study aimed to summarize the treatment experience of fractures in PWH based on a classification. Methods A retrospective cohort study was conducted on PWH between 2001 and 2023. The classification was developed into three types according to PWH’s clinical presentations and imaging findings. Subsequently, the distribution and distinctions among subtypes were analyzed, followed by an exploration of risk factors for fracture-related complications. Results A total of 61 fractures in PWH met the inclusion and exclusion criteria. The median follow-up duration was 6.87 years. Type II and III fractures in PWH exhibited a longer time of fracture healing and hospital stay, along with increased fracture-related complication rates. In further analysis, the operative time and intraoperative blood loss also increased significantly. Furthermore, compared to non-surgical approaches, the surgical treatment appeared to reduce the incidence of fracture-related complications. Next, the femur was identified as the most frequently fractured site. Plate fixation was the predominant surgical approach for types II (20/29) and III (8/13). Conclusion This study reviews treatment experience for fractures in PWH according to a classification and stresses the importance of surgery. The classification may provide a potential strategy for post-operative care. However, further classification is required.
- Open Access
- 6 March 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (5) , 2019-2039
Efficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review
Introduction Inhibitor development is a primary concern for pediatric patients with hemophilia A (HA) undergoing recombinant factor VIII (rFVIII) therapy, yet relevant research is lacking. We aimed to compare the efficacy and safety of standard (SHL) and extended half-life (EHL) rFVIII products in previously treated (PTPs) and untreated (PUPs) pediatric patients with HA. Methods Following PRISMA guidelines, we searched clinical studies from PubMed, Embase, and Cochrane Library. Data were extracted and a single-arm meta-analysis was performed. Results This systematic review included 16 studies involving 1145 patients. Three studies reported changes in annual bleeding rate (ABR); their results displayed no statistically significant difference in ABR changes in pediatric patients with HA after rFVIII treatment. Ten studies reported inhibitor development, nine focused on PUPs. Here, EHL rFVIII showed a proportion of inhibitors at 27.5% (95% confidence interval [CI] 22.6%; 32.6%), and third-generation SHL rFVIII showed a proportion of inhibitors at 36.4% (27.2%; 46.2%), with a high-titer proportion of 20.9% (12.9%; 30.3%) for the latter. Both SHL rFVIII (octocog alfa) and EHL rFVIII (rurioctocog alfa pegol) presented low proportions of inhibitor development. Octocog alfa exhibited the lowest high-titer inhibitor incidence, marked at 12.7% (5.3%; 24.5%). Eleven studies addressed adverse events (AEs), with octocog alfa showing low reported treatment-related AEs at a proportion of 14.5% (6.5%; 26.7%). Conclusion Our analysis revealed that both octocog alfa and rurioctocog alfa pegol showed low inhibitor development, with octocog alfa having few treatment-related AEs. Regular monitoring for inhibitors during rFVIII therapy is important.
- 6 March 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (5) , 2019-2039
Open AccessEfficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review
Introduction Inhibitor development is a primary concern for pediatric patients with hemophilia A (HA) undergoing recombinant factor VIII (rFVIII) therapy, yet relevant research is lacking. We aimed to compare the efficacy and safety of standard (SHL) and extended half-life (EHL) rFVIII products in previously treated (PTPs) and untreated (PUPs) pediatric patients with HA. Methods Following PRISMA guidelines, we searched clinical studies from PubMed, Embase, and Cochrane Library. Data were extracted and a single-arm meta-analysis was performed. Results This systematic review included 16 studies involving 1145 patients. Three studies reported changes in annual bleeding rate (ABR); their results displayed no statistically significant difference in ABR changes in pediatric patients with HA after rFVIII treatment. Ten studies reported inhibitor development, nine focused on PUPs. Here, EHL rFVIII showed a proportion of inhibitors at 27.5% (95% confidence interval [CI] 22.6%; 32.6%), and third-generation SHL rFVIII showed a proportion of inhibitors at 36.4% (27.2%; 46.2%), with a high-titer proportion of 20.9% (12.9%; 30.3%) for the latter. Both SHL rFVIII (octocog alfa) and EHL rFVIII (rurioctocog alfa pegol) presented low proportions of inhibitor development. Octocog alfa exhibited the lowest high-titer inhibitor incidence, marked at 12.7% (5.3%; 24.5%). Eleven studies addressed adverse events (AEs), with octocog alfa showing low reported treatment-related AEs at a proportion of 14.5% (6.5%; 26.7%). Conclusion Our analysis revealed that both octocog alfa and rurioctocog alfa pegol showed low inhibitor development, with octocog alfa having few treatment-related AEs. Regular monitoring for inhibitors during rFVIII therapy is important.
- 23 November 2022
- Published by Wiley in Haemophilia
- Vol. 29 (1) , 362-364
Relationship between serum cartilage turnover biomarkers and haemophilic arthropathy severity in adult patients with severe haemophilia A in China
- 23 November 2022
- Published by Wiley in Haemophilia
- Vol. 29 (1) , 362-364
Relationship between serum cartilage turnover biomarkers and haemophilic arthropathy severity in adult patients with severe haemophilia A in China
- Open Access
- 26 June 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-16
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Background: Despite the advantages of prophylactic treatment for hemophilia, patients tend to discontinue or not adhere to it because of several challenges such as long-term use, high cost, young patients transitioning to adolescents, and switch to self-infusion or self-care. The goal of this systematic literature review is to emphasize adherence to and efficiency of prophylactic treatment in adults. Methods: A literature review was conducted in PubMed, Embase, and Cochrane databases until April 2021 according to PRISMA guidelines, and the protocol was registered with PROSPERO (CRD42020220085). Studies evaluating the efficacy of prophylaxis in enhancing the quality of life were included. Results: A total of 31 articles involving 2379 patients with hemophilia were included in this systematic review. Of these, 26 studies were observational, questionnaire-based studies, and 5 were randomized controlled trials. The majority of studies reported lower annualized bleeding rates in patients receiving prophylaxis compared with those receiving on-demand treatment or those who discontinued prophylaxis. Standard-dose prophylaxis was reported to be effective in most of the studies. In developing countries like China, data suggest that low doses were administered because of limited available resources. However, standard dose or individualized prophylaxis should be provided to prevent joint damage in the long term. Compared with adults, greater adherence to treatment was observed in patients aged < 16 years. Conclusion: This systematic review emphasizes the importance of adherence to prophylaxis among young adults transitioning from childhood. In countries like China, low-dose prophylaxis can help in preventing joint bleeds in the short term, but in the long term, standard-dose therapy has shown high adherence among young adults and better joint health, in turn improving the quality of life.
- 26 June 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-16
Open AccessFactor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Background: Despite the advantages of prophylactic treatment for hemophilia, patients tend to discontinue or not adhere to it because of several challenges such as long-term use, high cost, young patients transitioning to adolescents, and switch to self-infusion or self-care. The goal of this systematic literature review is to emphasize adherence to and efficiency of prophylactic treatment in adults. Methods: A literature review was conducted in PubMed, Embase, and Cochrane databases until April 2021 according to PRISMA guidelines, and the protocol was registered with PROSPERO (CRD42020220085). Studies evaluating the efficacy of prophylaxis in enhancing the quality of life were included. Results: A total of 31 articles involving 2379 patients with hemophilia were included in this systematic review. Of these, 26 studies were observational, questionnaire-based studies, and 5 were randomized controlled trials. The majority of studies reported lower annualized bleeding rates in patients receiving prophylaxis compared with those receiving on-demand treatment or those who discontinued prophylaxis. Standard-dose prophylaxis was reported to be effective in most of the studies. In developing countries like China, data suggest that low doses were administered because of limited available resources. However, standard dose or individualized prophylaxis should be provided to prevent joint damage in the long term. Compared with adults, greater adherence to treatment was observed in patients aged < 16 years. Conclusion: This systematic review emphasizes the importance of adherence to prophylaxis among young adults transitioning from childhood. In countries like China, low-dose prophylaxis can help in preventing joint bleeds in the short term, but in the long term, standard-dose therapy has shown high adherence among young adults and better joint health, in turn improving the quality of life.